Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients

Abstract

BackgroundCytomegalovirus (CMV) infection has broad implications for morbidity and mortality in renal transplant recipients (RTR). Routine surveillance for CMV replication with PCR‐based quantitative nucleic acid testing (qNAT) assays is standard practice in most transplant centers, but the impact of assay sensitivity on antiviral decision‐making and virologic outcomes has not been studied. We investigated the effects of an ultrasensitive CMV qNAT assay on multiple clinical outcomes, including time to detection and duration of CMV DNAemia.MethodsWe conducted a single‐center cohort study contrasting RTRs monitored with a qNAT with a higher lower limit of quantification (LLOQ >300 IU/mL) with those monitored with a more sensitive qNAT (LLOQ >35 IU/mL). Patients were stratified by donor (D)/recipient (R) CMV serostatus (D+/R−: high risk; any R+: moderate risk). CMV viral load monitoring was performed monthly post transplantation, with the primary outcomes being time to CMV DNAemia and its duration.ResultsTotal 1382 patients were analyzed from 2014 to 2016 and 2019 to 2021. Moderate‐risk RTRs monitored with the more sensitive assay experienced a greater hazard for the development of a first episode of CMV DNAemia (aHR: 1.95, 95% confidence interval [CI]: 1.55–2.46) and an average of 24 (95% CI: 16.40–31.98) additional days of DNAemia. There was no difference in CMV end‐organ disease or 1‐year all‐cause mortality between moderate‐risk RTRs.ConclusionsThe more sensitive assay was associated with earlier detection and extended durations of CMV DNAemia in moderate‐risk RTRs, without altering clinical outcomes. These findings inform optimal use of these assays and antiviral stewardship in RTRs.Key SummaryThe use of ultrasensitive CMV qNAT assays in moderate‐risk CMV renal transplant recipients is associated with earlier detection and longer durations of CMV DNAemia without impacting CMV end‐organ disease or 1‐year mortality. image